Accendra Health, Inc.

Accendra Health, Inc.

ACH
Accendra Health, Inc.US flagNew York Stock Exchange
3.14
USD
+0.01
- -
240.47MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
144.85
151.72
157.33
159.16
155.3
156.93
152.06
133.82
134.52
133.64
33.68
34.92
35.92
35.35
Basic EPS, GAAP
1.77
1.06
1.65
1.76
1.21
-7.28
-1.03
0.47
3.05
0.3
-0.54
-4.73
-14.31
-14.08
Free Cash Flow per Basic Share
1.28
-1.2
3.76
2.58
0.1
0.83
1.88
4.42
1.02
2.13
7.42
-0.28
-3.94
-4.07
Dividend per Share
0.97
1.01
1.02
1.04
1.05
0.8
0.09
0.01
0.01
- -
- -
- -
- -
- -
Book Value per Share
13.06
13.05
13.4
13.22
13.56
5.42
4.35
4.95
7.4
7.55
6.89
2.37
-12.05
-12.14
Tangible Book Value per Share
11.32
7.38
7.69
7.57
1.95
-3.5
-3.57
1.18
4.65
-15.25
-14.2
-11.1
-23.74
-23.43
Basic Weighted Avg Shares
63
62
62
61
60
60
61
63
73
74
76
77
77
77
Sales/Revenue/Turnover
9,072
9,440
9,773
9,723
9,318
9,418
9,211
8,480
9,785
9,955
2,553
2,680
2,762
2,716
Operating Margin (%)
2.32
2.14
2.34
2.31
1.61
1.28
1.12
2.85
4.52
2.78
8.44
7.39
8.03
6.91
Depreciation Expense
51
63
66
55
59
102
117
93
91
229
210
181
215
233
Net Income, GAAP
111
67
103
109
73
-437
-62
30
222
22
-41
-363
-1,101
-1,082
Effective Tax Rate (%)
40.06
47.42
40.3
36.95
- -
- -
- -
19.87
19.93
- -
41.66
- -
- -
- -
Profit Margin (%)
1.22
0.7
1.06
1.12
0.78
-4.64
-0.68
0.35
2.26
0.22
-1.62
-13.53
-39.85
-39.84
Working Capital
736
903
911
927
872
1,067
991
790
978
729
211
169
-399
-615
LT Debt
213
609
568
565
901
1,648
1,625
1,106
1,110
2,698
2,113
1,888
1,870
1,589
Total Equity
1,025
991
993
960
1,015
518
462
712
939
946
924
586
-461
-465
Return on Invested Capital (%)
10.17
7.37
8.61
9.25
- -
- -
- -
10.03
18.5
- -
3.65
- -
- -
- -
Return on Capital (%)
11.68
6.2
8.48
9.08
- -
- -
- -
5.84
16.95
- -
0.88
- -
- -
- -
Return on Common Equity (%)
13.83
8.09
12.46
13.13
8.98
-76.74
-21.19
10.35
51.99
4.07
-7.62
-103.13
- -
- -

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
280
250
581
LT Borrowings
1,835
1,800
1,522
LT Finance Leases
81
70
67
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
77
76
77
Market Capitalization
370
216
175

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
2,132
548
588
Cash, Cash Equivalents & STI
33
282
337
Accounts Receivable, Net
170
96
104
Inventories
64
74
65
Total Current Liabilities
2,466
947
1,203
Payables & Accruals
385
433
408
ST Debt
280
250
581
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-18.81%
-36.98%
-178.62%
Free Cash Flow
239.42%
304.44%
1,331.81%
Net Income, GAAP
28.72%
249.81%
203.47%
Sales/Revenue/Turnover
-6.29%
-9.83%
3.06%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,613
660
687
2,696
2,680
2025
674
682
697
709
2,762
2026
628
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.29
-0.42
-0.17
-3.84
-4.73
2025
-0.32
-11.3
-1.94
-0.73
-14.31
2026
-0.08
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Edward A. Pesicka
Full Time Employees
6,500
Sector
Healthcare
Industry
Medical - Distribution
Address
10900 Nuckols Road Glen Allen VA United States of America 23060
IPO Date
Mar 17, 1980
Business
Aluminum Corporation of China Limited Aluminum Corporation of China Limited (Chalco) engages in the production and sale of alumina, primary aluminum, aluminum alloy products, aluminum ores, bauxite, coal, carbon products, fabricated aluminum products, fabricated copper products, rare metals and rare earth; it operates through segments including alumina refining, primary aluminum smelting, energy generation via thermal power and new energy sources, trading, mining of bauxite and other resources, engineering and technical services, international joint ventures, and logistics. Headquartered in Beijing, China, and founded in 2001 as a holding subsidiary of Aluminum Corporation of China (Chinalco), the company maintains primary operations in China with overseas activities in Peru's Toromocho copper mine producing copper, silver, and molybdenum, and participation in Guinea's Simandou iron ore project alongside partners including Rio Tinto. Recent developments include the commissioning of a 400,000-tonne-per-year green aluminum smelter in Yunnan Province powered by hydropower in early 2024 to support decarbonization efforts; plans announced in late 2024 to acquire slab ingot assets from Chinalco High-end Manufacturing; establishment of a joint venture in 2025 with Chinalco, Yunnan Copper, Chihong Zinc & Germanium, registered capital RMB1,500 million; and scheduling of a 2025 extraordinary general meeting to approve connected transactions with Chinalco covering logistics, production supplies, mineral supply, and financial services.

Company News

APIChatGPT
  • Is the Options Market Predicting a Spike in Accendra Health Stock?

  • Accendra Health Announces Expiration and Final Results of Offers and Consent Solicitations

  • Accendra Health Announces Expiration and Final Results of Offers and Consent Solicitations

  • Accendra Health Announces Early Results of Offers and Consent Solicitations

  • Accendra Health Announces Early Results of Offers and Consent Solicitations

  • Accendra Health Announces Offers and Consent Solicitations

  • Accendra Health, Inc. (ACH) Shareholder/Analyst Call Prepared Remarks Transcript

  • Accendra Health Makes Progress Addressing Its Debt Load

  • Accendra Health, Inc. (ACH) Q1 2026 Earnings Call Transcript

  • Accendra Health Reports First Quarter 2026 Financial Results and Announces Comprehensive Balance Sheet Optimization Transaction

  • Accendra Health Announces First Quarter 2026 Earnings Release Date and Conference Call

  • Is the Options Market Predicting a Spike in Accendra Health Stock?

  • Alkami Now a Nacha Preferred Partner for ACH Experience, Fraud Monitoring, and Risk and Fraud Prevention

  • Accendra Health: Debt Reduction Creates Long-Term Opportunity (Upgrade)

  • Accendra Health, Inc. (ACH) Q4 2025 Earnings Call Transcript

  • Accendra Health Reports Fourth Quarter 2025 Financial Results

  • HARBOR CAPITAL ADVISORS, INC. Sells 269 Shares of Ascendis Pharma AS (ASND)

  • Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

  • Accendra Health, Inc. to Begin Trading on NYSE under New Ticker “ACH”

  • Nextech3D.ai introduces digital payment upgrades with crypto and ACH integration